Heritage Pharmaceuticals – Recall of amikacin and prochlorperazine injection products

- On May 28, 2019, Heritage Pharmaceuticals announced a consumer-level recall of two lots of amikacin injection and prochlorperazine injection due to microbial growth having been detected in a couple unreleased sublots, which may indicate a lack of sterility in the other sublots.

- The recalled amikacin injection lot and prochlorperazine injection lot were distributed nationwide between June 2018 - August 2018, and October 2018 - November 2018, respectively:

Product Description	NDC#	Lot# (Expiration Date)
Amikacin sulfate injection, 1 g/4 mL (250 mg/mL)	23155-290-42	VEAC025 (10/2019)
Prochlorperazine edisylate injection, 10 mg/2 mL (5 mg/mL)	23155-294-42	VPCA172 (4/2020)

- Amikacin injection is indicated in the short-term treatment of serious infections due to susceptible strains of certain types of Gram-negative bacteria.

- Prochlorperazine injection is indicated to control severe nausea and vomiting and for the treatment of schizophrenia.

- Per Heritage, administration of non-sterile injectable products that are intended to be sterile may result in a site-specific or systemic infection, which in turn may cause hospitalization, organ damage or death.

- To date, Heritage has not received adverse event reports related to the recalled products.

- Patients should contact their healthcare provider for further guidance and potential change of treatment before they stop taking the recalled products.

- Patients should contact their healthcare provider if they have experienced any problems that may be related to using the recalled amikacin injection or prochlorperazine injection.

- Pharmacies and healthcare facilities that have the recalled drug products should immediately quarantine and stop dispensing the recalled drug products.

- For more information regarding this recall, contact Qualanex (appointed company for Heritage) by phone at **1-800-505-9291** or by email at **recall@qualanex.com**.